nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—NPPB—cardiovascular system—nicotine dependence	0.0242	0.0917	CbGeAlD
Carvedilol—Peripheral ischaemia—Varenicline—nicotine dependence	0.0191	0.0408	CcSEcCtD
Carvedilol—SELE—cardiovascular system—nicotine dependence	0.0163	0.0619	CbGeAlD
Carvedilol—Depressed mood—Varenicline—nicotine dependence	0.0156	0.0333	CcSEcCtD
Carvedilol—VCAM1—cardiovascular system—nicotine dependence	0.015	0.057	CbGeAlD
Carvedilol—HIF1A—cardiovascular system—nicotine dependence	0.0144	0.0548	CbGeAlD
Carvedilol—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0142	0.0303	CcSEcCtD
Carvedilol—Sinus congestion—Varenicline—nicotine dependence	0.014	0.0299	CcSEcCtD
Carvedilol—GJA1—cardiovascular system—nicotine dependence	0.014	0.0532	CbGeAlD
Carvedilol—SELE—midbrain—nicotine dependence	0.0127	0.0484	CbGeAlD
Carvedilol—Sleep disturbance—Varenicline—nicotine dependence	0.0125	0.0265	CcSEcCtD
Carvedilol—NDUFC2—cardiovascular system—nicotine dependence	0.0122	0.0463	CbGeAlD
Carvedilol—NPPB—brain—nicotine dependence	0.0119	0.045	CbGeAlD
Carvedilol—VCAM1—midbrain—nicotine dependence	0.0117	0.0445	CbGeAlD
Carvedilol—HIF1A—midbrain—nicotine dependence	0.0113	0.0428	CbGeAlD
Carvedilol—Psoriasis—Varenicline—nicotine dependence	0.0111	0.0237	CcSEcCtD
Carvedilol—GJA1—midbrain—nicotine dependence	0.0109	0.0415	CbGeAlD
Carvedilol—Paranoia—Varenicline—nicotine dependence	0.0102	0.0218	CcSEcCtD
Carvedilol—NDUFC2—midbrain—nicotine dependence	0.00952	0.0361	CbGeAlD
Carvedilol—Glycosuria—Varenicline—nicotine dependence	0.00862	0.0184	CcSEcCtD
Carvedilol—Disturbance in attention—Varenicline—nicotine dependence	0.00806	0.0172	CcSEcCtD
Carvedilol—SELE—brain—nicotine dependence	0.00801	0.0304	CbGeAlD
Carvedilol—Accidental injury—Varenicline—nicotine dependence	0.00789	0.0168	CcSEcCtD
Carvedilol—Viral infection—Varenicline—nicotine dependence	0.00773	0.0165	CcSEcCtD
Carvedilol—Thinking abnormal—Varenicline—nicotine dependence	0.00763	0.0162	CcSEcCtD
Carvedilol—VCAM1—brain—nicotine dependence	0.00737	0.028	CbGeAlD
Carvedilol—HIF1A—brain—nicotine dependence	0.00709	0.0269	CbGeAlD
Carvedilol—GJA1—brain—nicotine dependence	0.00687	0.0261	CbGeAlD
Carvedilol—Hyperkalaemia—Varenicline—nicotine dependence	0.00686	0.0146	CcSEcCtD
Carvedilol—Nightmare—Varenicline—nicotine dependence	0.00674	0.0144	CcSEcCtD
Carvedilol—Mental disability—Varenicline—nicotine dependence	0.00606	0.0129	CcSEcCtD
Carvedilol—NDUFC2—brain—nicotine dependence	0.00598	0.0227	CbGeAlD
Carvedilol—Sleep disorder—Varenicline—nicotine dependence	0.00585	0.0125	CcSEcCtD
Carvedilol—Diabetes mellitus—Varenicline—nicotine dependence	0.00583	0.0124	CcSEcCtD
Carvedilol—Tamsulosin—DRD2—nicotine dependence	0.00577	1	CrCbGaD
Carvedilol—Injury—Varenicline—nicotine dependence	0.00551	0.0117	CcSEcCtD
Carvedilol—Renal failure acute—Varenicline—nicotine dependence	0.00549	0.0117	CcSEcCtD
Carvedilol—Libido decreased—Varenicline—nicotine dependence	0.00547	0.0116	CcSEcCtD
Carvedilol—VEGFA—brain—nicotine dependence	0.00543	0.0206	CbGeAlD
Carvedilol—Amnesia—Varenicline—nicotine dependence	0.00539	0.0115	CcSEcCtD
Carvedilol—Atrial fibrillation—Varenicline—nicotine dependence	0.00535	0.0114	CcSEcCtD
Carvedilol—ADRB1—cardiovascular system—nicotine dependence	0.00525	0.0199	CbGeAlD
Carvedilol—Arthritis—Varenicline—nicotine dependence	0.00521	0.0111	CcSEcCtD
Carvedilol—Hypoglycaemia—Varenicline—nicotine dependence	0.00519	0.0111	CcSEcCtD
Carvedilol—Cerebrovascular accident—Varenicline—nicotine dependence	0.00517	0.011	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00507	0.0108	CcSEcCtD
Carvedilol—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00503	0.0107	CcSEcCtD
Carvedilol—Affect lability—Varenicline—nicotine dependence	0.00499	0.0106	CcSEcCtD
Carvedilol—Migraine—Varenicline—nicotine dependence	0.00499	0.0106	CcSEcCtD
Carvedilol—Psychotic disorder—Varenicline—nicotine dependence	0.00495	0.0105	CcSEcCtD
Carvedilol—Mood swings—Varenicline—nicotine dependence	0.0048	0.0102	CcSEcCtD
Carvedilol—Hypokalaemia—Varenicline—nicotine dependence	0.00461	0.00982	CcSEcCtD
Carvedilol—Cramp muscle—Varenicline—nicotine dependence	0.00456	0.00972	CcSEcCtD
Carvedilol—Nasopharyngitis—Varenicline—nicotine dependence	0.00453	0.00965	CcSEcCtD
Carvedilol—Angina pectoris—Varenicline—nicotine dependence	0.00427	0.00909	CcSEcCtD
Carvedilol—Bronchitis—Varenicline—nicotine dependence	0.00421	0.00897	CcSEcCtD
Carvedilol—ADRA1A—cardiovascular system—nicotine dependence	0.00415	0.0158	CbGeAlD
Carvedilol—Pollakiuria—Varenicline—nicotine dependence	0.00405	0.00862	CcSEcCtD
Carvedilol—Erectile dysfunction—Varenicline—nicotine dependence	0.00403	0.00859	CcSEcCtD
Carvedilol—KCNH2—cardiovascular system—nicotine dependence	0.00401	0.0152	CbGeAlD
Carvedilol—Photosensitivity reaction—Varenicline—nicotine dependence	0.004	0.00852	CcSEcCtD
Carvedilol—Weight increased—Varenicline—nicotine dependence	0.00399	0.00849	CcSEcCtD
Carvedilol—Hyperglycaemia—Varenicline—nicotine dependence	0.00395	0.00842	CcSEcCtD
Carvedilol—Depression—Varenicline—nicotine dependence	0.00389	0.00829	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00387	0.00825	CcSEcCtD
Carvedilol—Acute coronary syndrome—Varenicline—nicotine dependence	0.00385	0.0082	CcSEcCtD
Carvedilol—Myocardial infarction—Varenicline—nicotine dependence	0.00383	0.00815	CcSEcCtD
Carvedilol—Sinusitis—Varenicline—nicotine dependence	0.00366	0.0078	CcSEcCtD
Carvedilol—ADRA1B—brain—nicotine dependence	0.00363	0.0138	CbGeAlD
Carvedilol—Bradycardia—Varenicline—nicotine dependence	0.00357	0.0076	CcSEcCtD
Carvedilol—ADRA1D—brain—nicotine dependence	0.00355	0.0135	CbGeAlD
Carvedilol—Hypoaesthesia—Varenicline—nicotine dependence	0.00349	0.00743	CcSEcCtD
Carvedilol—Urinary tract disorder—Varenicline—nicotine dependence	0.00346	0.00737	CcSEcCtD
Carvedilol—Oedema peripheral—Varenicline—nicotine dependence	0.00345	0.00736	CcSEcCtD
Carvedilol—Urethral disorder—Varenicline—nicotine dependence	0.00344	0.00732	CcSEcCtD
Carvedilol—Visual impairment—Varenicline—nicotine dependence	0.00338	0.0072	CcSEcCtD
Carvedilol—Erythema multiforme—Varenicline—nicotine dependence	0.00331	0.00706	CcSEcCtD
Carvedilol—Tinnitus—Varenicline—nicotine dependence	0.00327	0.00696	CcSEcCtD
Carvedilol—CYP2C9—cardiovascular system—nicotine dependence	0.00326	0.0124	CbGeAlD
Carvedilol—Angiopathy—Varenicline—nicotine dependence	0.00318	0.00678	CcSEcCtD
Carvedilol—Immune system disorder—Varenicline—nicotine dependence	0.00317	0.00674	CcSEcCtD
Carvedilol—Mediastinal disorder—Varenicline—nicotine dependence	0.00316	0.00673	CcSEcCtD
Carvedilol—KCNH2—midbrain—nicotine dependence	0.00313	0.0119	CbGeAlD
Carvedilol—ADRA2C—midbrain—nicotine dependence	0.00309	0.0117	CbGeAlD
Carvedilol—CYP2E1—cardiovascular system—nicotine dependence	0.00309	0.0117	CbGeAlD
Carvedilol—Malnutrition—Varenicline—nicotine dependence	0.00305	0.0065	CcSEcCtD
Carvedilol—Flatulence—Varenicline—nicotine dependence	0.00301	0.00641	CcSEcCtD
Carvedilol—PTGS1—cardiovascular system—nicotine dependence	0.00297	0.0113	CbGeAlD
Carvedilol—Back pain—Varenicline—nicotine dependence	0.00295	0.00629	CcSEcCtD
Carvedilol—Muscle spasms—Varenicline—nicotine dependence	0.00293	0.00625	CcSEcCtD
Carvedilol—Vision blurred—Varenicline—nicotine dependence	0.00288	0.00613	CcSEcCtD
Carvedilol—Ill-defined disorder—Varenicline—nicotine dependence	0.00283	0.00603	CcSEcCtD
Carvedilol—Anaemia—Varenicline—nicotine dependence	0.00282	0.00601	CcSEcCtD
Carvedilol—Angioedema—Varenicline—nicotine dependence	0.00279	0.00594	CcSEcCtD
Carvedilol—Malaise—Varenicline—nicotine dependence	0.00275	0.00586	CcSEcCtD
Carvedilol—Vertigo—Varenicline—nicotine dependence	0.00274	0.00584	CcSEcCtD
Carvedilol—Syncope—Varenicline—nicotine dependence	0.00274	0.00583	CcSEcCtD
Carvedilol—Palpitations—Varenicline—nicotine dependence	0.0027	0.00574	CcSEcCtD
Carvedilol—Loss of consciousness—Varenicline—nicotine dependence	0.00268	0.00571	CcSEcCtD
Carvedilol—Cough—Varenicline—nicotine dependence	0.00266	0.00567	CcSEcCtD
Carvedilol—Convulsion—Varenicline—nicotine dependence	0.00264	0.00563	CcSEcCtD
Carvedilol—Hypertension—Varenicline—nicotine dependence	0.00264	0.00561	CcSEcCtD
Carvedilol—Arthralgia—Varenicline—nicotine dependence	0.0026	0.00553	CcSEcCtD
Carvedilol—Chest pain—Varenicline—nicotine dependence	0.0026	0.00553	CcSEcCtD
Carvedilol—Myalgia—Varenicline—nicotine dependence	0.0026	0.00553	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00258	0.0055	CcSEcCtD
Carvedilol—ADRB1—brain—nicotine dependence	0.00258	0.00978	CbGeAlD
Carvedilol—Discomfort—Varenicline—nicotine dependence	0.00257	0.00547	CcSEcCtD
Carvedilol—Dry mouth—Varenicline—nicotine dependence	0.00254	0.00541	CcSEcCtD
Carvedilol—Oedema—Varenicline—nicotine dependence	0.00249	0.00531	CcSEcCtD
Carvedilol—Infection—Varenicline—nicotine dependence	0.00247	0.00527	CcSEcCtD
Carvedilol—ADRA2A—midbrain—nicotine dependence	0.00246	0.00936	CbGeAlD
Carvedilol—Shock—Varenicline—nicotine dependence	0.00245	0.00522	CcSEcCtD
Carvedilol—Thrombocytopenia—Varenicline—nicotine dependence	0.00244	0.00519	CcSEcCtD
Carvedilol—Tachycardia—Varenicline—nicotine dependence	0.00243	0.00518	CcSEcCtD
Carvedilol—Skin disorder—Varenicline—nicotine dependence	0.00242	0.00515	CcSEcCtD
Carvedilol—Hyperhidrosis—Varenicline—nicotine dependence	0.00241	0.00513	CcSEcCtD
Carvedilol—Anorexia—Varenicline—nicotine dependence	0.00237	0.00506	CcSEcCtD
Carvedilol—Hypotension—Varenicline—nicotine dependence	0.00233	0.00496	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00227	0.00483	CcSEcCtD
Carvedilol—Insomnia—Varenicline—nicotine dependence	0.00225	0.0048	CcSEcCtD
Carvedilol—Dyspnoea—Varenicline—nicotine dependence	0.00222	0.00473	CcSEcCtD
Carvedilol—Somnolence—Varenicline—nicotine dependence	0.00221	0.00472	CcSEcCtD
Carvedilol—Dyspepsia—Varenicline—nicotine dependence	0.00219	0.00467	CcSEcCtD
Carvedilol—Decreased appetite—Varenicline—nicotine dependence	0.00217	0.00461	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00215	0.00458	CcSEcCtD
Carvedilol—Fatigue—Varenicline—nicotine dependence	0.00215	0.00457	CcSEcCtD
Carvedilol—Pain—Varenicline—nicotine dependence	0.00213	0.00454	CcSEcCtD
Carvedilol—Constipation—Varenicline—nicotine dependence	0.00213	0.00454	CcSEcCtD
Carvedilol—Feeling abnormal—Varenicline—nicotine dependence	0.00205	0.00437	CcSEcCtD
Carvedilol—ADRA1A—brain—nicotine dependence	0.00204	0.00773	CbGeAlD
Carvedilol—Gastrointestinal pain—Varenicline—nicotine dependence	0.00204	0.00434	CcSEcCtD
Carvedilol—Urticaria—Varenicline—nicotine dependence	0.00198	0.00421	CcSEcCtD
Carvedilol—Body temperature increased—Varenicline—nicotine dependence	0.00197	0.00419	CcSEcCtD
Carvedilol—Abdominal pain—Varenicline—nicotine dependence	0.00197	0.00419	CcSEcCtD
Carvedilol—KCNH2—brain—nicotine dependence	0.00197	0.00747	CbGeAlD
Carvedilol—ADRA2C—brain—nicotine dependence	0.00194	0.00737	CbGeAlD
Carvedilol—Hypersensitivity—Varenicline—nicotine dependence	0.00184	0.00391	CcSEcCtD
Carvedilol—Asthenia—Varenicline—nicotine dependence	0.00179	0.00381	CcSEcCtD
Carvedilol—Pruritus—Varenicline—nicotine dependence	0.00176	0.00375	CcSEcCtD
Carvedilol—ABCB1—cardiovascular system—nicotine dependence	0.00176	0.00668	CbGeAlD
Carvedilol—Diarrhoea—Varenicline—nicotine dependence	0.0017	0.00363	CcSEcCtD
Carvedilol—CYP1A1—brain—nicotine dependence	0.00166	0.00631	CbGeAlD
Carvedilol—Dizziness—Varenicline—nicotine dependence	0.00165	0.00351	CcSEcCtD
Carvedilol—Vomiting—Varenicline—nicotine dependence	0.00158	0.00337	CcSEcCtD
Carvedilol—Rash—Varenicline—nicotine dependence	0.00157	0.00335	CcSEcCtD
Carvedilol—Dermatitis—Varenicline—nicotine dependence	0.00157	0.00334	CcSEcCtD
Carvedilol—Headache—Varenicline—nicotine dependence	0.00156	0.00332	CcSEcCtD
Carvedilol—ADRA2A—brain—nicotine dependence	0.00155	0.00588	CbGeAlD
Carvedilol—CYP2E1—brain—nicotine dependence	0.00152	0.00575	CbGeAlD
Carvedilol—Nausea—Varenicline—nicotine dependence	0.00148	0.00315	CcSEcCtD
Carvedilol—PTGS1—brain—nicotine dependence	0.00146	0.00554	CbGeAlD
Carvedilol—ABCB1—midbrain—nicotine dependence	0.00137	0.00521	CbGeAlD
Carvedilol—CYP2D6—brain—nicotine dependence	0.0012	0.00455	CbGeAlD
Carvedilol—VCAM1—Immune System—WASF2—nicotine dependence	0.000906	0.00347	CbGpPWpGaD
Carvedilol—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000902	0.00345	CbGpPWpGaD
Carvedilol—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0009	0.00345	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—TAS2R16—nicotine dependence	0.0009	0.00344	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—TAS2R16—nicotine dependence	0.000892	0.00341	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00088	0.00337	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—WASF1—nicotine dependence	0.000869	0.00332	CbGpPWpGaD
Carvedilol—ABCB1—brain—nicotine dependence	0.000863	0.00328	CbGeAlD
Carvedilol—ADRB3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000857	0.00328	CbGpPWpGaD
Carvedilol—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000849	0.00325	CbGpPWpGaD
Carvedilol—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.000849	0.00325	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000839	0.00321	CbGpPWpGaD
Carvedilol—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000837	0.0032	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—FGD1—nicotine dependence	0.000834	0.00319	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.000833	0.00319	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00082	0.00314	CbGpPWpGaD
Carvedilol—KCNH2—Neuronal System—CHRNB2—nicotine dependence	0.000814	0.00312	CbGpPWpGaD
Carvedilol—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.0008	0.00306	CbGpPWpGaD
Carvedilol—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000789	0.00302	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000778	0.00298	CbGpPWpGaD
Carvedilol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000741	0.00284	CbGpPWpGaD
Carvedilol—KCNH2—Neuronal System—CHRNA4—nicotine dependence	0.000739	0.00283	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000737	0.00282	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000728	0.00279	CbGpPWpGaD
Carvedilol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000708	0.00271	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000676	0.00259	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—FGD1—nicotine dependence	0.000672	0.00257	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—OPRM1—nicotine dependence	0.000639	0.00245	CbGpPWpGaD
Carvedilol—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000639	0.00245	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000638	0.00244	CbGpPWpGaD
Carvedilol—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000633	0.00242	CbGpPWpGaD
Carvedilol—ADRA2B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000621	0.00238	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—FGD1—nicotine dependence	0.000611	0.00234	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000607	0.00232	CbGpPWpGaD
Carvedilol—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000602	0.0023	CbGpPWpGaD
Carvedilol—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000597	0.00228	CbGpPWpGaD
Carvedilol—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000594	0.00227	CbGpPWpGaD
Carvedilol—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000589	0.00225	CbGpPWpGaD
Carvedilol—ADRB1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000581	0.00223	CbGpPWpGaD
Carvedilol—ADRA2C—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00058	0.00222	CbGpPWpGaD
Carvedilol—ADRA2B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000576	0.00221	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000569	0.00218	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000558	0.00214	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000547	0.00209	CbGpPWpGaD
Carvedilol—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000541	0.00207	CbGpPWpGaD
Carvedilol—ADRA2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000538	0.00206	CbGpPWpGaD
Carvedilol—ADRA1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00053	0.00203	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—WASF2—nicotine dependence	0.000519	0.00199	CbGpPWpGaD
Carvedilol—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00051	0.00195	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000509	0.00195	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.000507	0.00194	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000504	0.00193	CbGpPWpGaD
Carvedilol—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000503	0.00193	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000498	0.00191	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—WASF1—nicotine dependence	0.000498	0.0019	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000497	0.0019	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000494	0.00189	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000487	0.00187	CbGpPWpGaD
Carvedilol—ADRA2A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000471	0.0018	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000471	0.0018	CbGpPWpGaD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00047	0.0018	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000463	0.00177	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—DRD2—nicotine dependence	0.000462	0.00177	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000462	0.00177	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000461	0.00177	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000461	0.00176	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TAS2R16—nicotine dependence	0.00046	0.00176	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TAS2R16—nicotine dependence	0.000459	0.00176	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000458	0.00175	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000454	0.00174	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000452	0.00173	CbGpPWpGaD
Carvedilol—ADRA2B—G alpha (i) signalling events—DRD2—nicotine dependence	0.000449	0.00172	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—OPRM1—nicotine dependence	0.000448	0.00171	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—FGD1—nicotine dependence	0.000438	0.00168	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000437	0.00167	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.000427	0.00164	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000421	0.00161	CbGpPWpGaD
Carvedilol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00042	0.00161	CbGpPWpGaD
Carvedilol—ADRA2C—G alpha (i) signalling events—DRD2—nicotine dependence	0.000419	0.0016	CbGpPWpGaD
Carvedilol—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000418	0.0016	CbGpPWpGaD
Carvedilol—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000417	0.00159	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—OPRM1—nicotine dependence	0.000416	0.00159	CbGpPWpGaD
Carvedilol—XDH—Metabolism—CYP2A7—nicotine dependence	0.000415	0.00159	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000411	0.00157	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000411	0.00157	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000403	0.00154	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—FGD1—nicotine dependence	0.000399	0.00153	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—FGD1—nicotine dependence	0.000398	0.00152	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—FGD1—nicotine dependence	0.000395	0.00151	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000395	0.00151	CbGpPWpGaD
Carvedilol—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000394	0.00151	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—FGD1—nicotine dependence	0.00039	0.00149	CbGpPWpGaD
Carvedilol—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000389	0.00149	CbGpPWpGaD
Carvedilol—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000388	0.00149	CbGpPWpGaD
Carvedilol—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000383	0.00147	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000382	0.00146	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—OPRM1—nicotine dependence	0.000379	0.00145	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—OPRM1—nicotine dependence	0.000376	0.00144	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000375	0.00143	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000374	0.00143	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—OPRM1—nicotine dependence	0.000371	0.00142	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—FGD1—nicotine dependence	0.000369	0.00141	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—FGD1—nicotine dependence	0.000363	0.00139	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—FGD1—nicotine dependence	0.000362	0.00139	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—OPRM1—nicotine dependence	0.000361	0.00138	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—FGD1—nicotine dependence	0.000361	0.00138	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00036	0.00138	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—FGD1—nicotine dependence	0.00036	0.00138	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—FGD1—nicotine dependence	0.000359	0.00137	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000357	0.00137	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—FGD1—nicotine dependence	0.000354	0.00136	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000352	0.00135	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—OPRM1—nicotine dependence	0.000351	0.00134	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000347	0.00133	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000346	0.00132	CbGpPWpGaD
Carvedilol—ADRA2A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000341	0.0013	CbGpPWpGaD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00034	0.0013	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—FGD1—nicotine dependence	0.000335	0.00128	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000333	0.00128	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—FGD1—nicotine dependence	0.00033	0.00126	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000328	0.00126	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—OPRM1—nicotine dependence	0.000328	0.00126	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—DRD2—nicotine dependence	0.000324	0.00124	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000323	0.00124	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKR1B10—nicotine dependence	0.000319	0.00122	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKR1B10—nicotine dependence	0.000318	0.00122	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000316	0.00121	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000307	0.00117	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—DRD2—nicotine dependence	0.000301	0.00115	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—FGD1—nicotine dependence	0.0003	0.00115	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000299	0.00115	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—FGD1—nicotine dependence	0.000293	0.00112	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000291	0.00112	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000285	0.00109	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—DRD2—nicotine dependence	0.000274	0.00105	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TAS2R16—nicotine dependence	0.000273	0.00104	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—FGD1—nicotine dependence	0.000272	0.00104	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—DRD2—nicotine dependence	0.000272	0.00104	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000271	0.00104	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TAS2R16—nicotine dependence	0.00027	0.00103	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—DRD2—nicotine dependence	0.000268	0.00103	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TAS2R16—nicotine dependence	0.000267	0.00102	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—DRD2—nicotine dependence	0.000261	0.000999	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—DRD2—nicotine dependence	0.000254	0.000972	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000252	0.000966	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—DRD2—nicotine dependence	0.00025	0.000956	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000248	0.000951	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—DRD2—nicotine dependence	0.000237	0.000908	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000235	0.000901	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FGD1—nicotine dependence	0.000235	0.000899	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000233	0.000893	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—WASF2—nicotine dependence	0.000224	0.000859	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—WASF2—nicotine dependence	0.000224	0.000857	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—DRD2—nicotine dependence	0.000222	0.000849	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000221	0.000845	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—WASF1—nicotine dependence	0.000215	0.000824	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—WASF1—nicotine dependence	0.000215	0.000822	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000214	0.00082	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FGD1—nicotine dependence	0.000214	0.000819	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—OPRM1—nicotine dependence	0.000214	0.000818	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000212	0.000813	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FGD1—nicotine dependence	0.000212	0.000812	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—OPRM1—nicotine dependence	0.00021	0.000803	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FGD1—nicotine dependence	0.000209	0.000801	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000208	0.000794	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—DRD2—nicotine dependence	0.000206	0.000789	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000205	0.000785	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.000198	0.000759	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FGD1—nicotine dependence	0.000198	0.000758	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000195	0.000747	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FGD1—nicotine dependence	0.000195	0.000746	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—OPRM1—nicotine dependence	0.000195	0.000745	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CYP2A7—nicotine dependence	0.000195	0.000745	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CYP2A7—nicotine dependence	0.000194	0.000743	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—OPRM1—nicotine dependence	0.000194	0.000742	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—OPRM1—nicotine dependence	0.000193	0.00074	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—OPRM1—nicotine dependence	0.000193	0.000738	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—OPRM1—nicotine dependence	0.00019	0.000729	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKR1B10—nicotine dependence	0.000189	0.000724	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKR1B10—nicotine dependence	0.000187	0.000717	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKR1B10—nicotine dependence	0.000185	0.000708	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—OPRM1—nicotine dependence	0.00018	0.00069	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000177	0.000679	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000175	0.00067	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000173	0.000664	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FGD1—nicotine dependence	0.000173	0.000663	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000172	0.000659	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—DRD2—nicotine dependence	0.00017	0.000651	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000161	0.000617	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGD1—nicotine dependence	0.000161	0.000616	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CYP2A7—nicotine dependence	0.000158	0.000605	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000158	0.000603	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—DRD2—nicotine dependence	0.000155	0.000593	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—DRD2—nicotine dependence	0.000154	0.000591	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—DRD2—nicotine dependence	0.000154	0.000588	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000153	0.000586	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—DRD2—nicotine dependence	0.000152	0.00058	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000146	0.00056	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—WASF2—nicotine dependence	0.000146	0.00056	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000145	0.000555	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—DRD2—nicotine dependence	0.000143	0.000549	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000142	0.000544	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000141	0.00054	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—DRD2—nicotine dependence	0.000141	0.000539	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—WASF1—nicotine dependence	0.00014	0.000537	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—DRD2—nicotine dependence	0.00014	0.000536	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—DRD2—nicotine dependence	0.00014	0.000535	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—DRD2—nicotine dependence	0.000139	0.000534	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—DRD2—nicotine dependence	0.000138	0.000527	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000137	0.000524	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—WASF2—nicotine dependence	0.000133	0.00051	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—WASF2—nicotine dependence	0.000132	0.000505	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—WASF2—nicotine dependence	0.00013	0.000499	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—DRD2—nicotine dependence	0.00013	0.000499	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—DRD2—nicotine dependence	0.000128	0.000491	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—WASF1—nicotine dependence	0.000128	0.000489	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—WASF1—nicotine dependence	0.000127	0.000484	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—OPRM1—nicotine dependence	0.000126	0.000483	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000125	0.00048	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—WASF1—nicotine dependence	0.000125	0.000478	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—WASF2—nicotine dependence	0.000123	0.000472	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—WASF2—nicotine dependence	0.000121	0.000464	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—WASF1—nicotine dependence	0.000118	0.000452	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000117	0.000446	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—WASF1—nicotine dependence	0.000116	0.000445	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—OPRM1—nicotine dependence	0.000115	0.00044	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—OPRM1—nicotine dependence	0.000114	0.000436	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—DRD2—nicotine dependence	0.000114	0.000436	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—OPRM1—nicotine dependence	0.000112	0.000431	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000109	0.000418	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—WASF2—nicotine dependence	0.000108	0.000413	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—OPRM1—nicotine dependence	0.000106	0.000407	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—DRD2—nicotine dependence	0.000106	0.000405	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—OPRM1—nicotine dependence	0.000105	0.000401	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—WASF1—nicotine dependence	0.000103	0.000396	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000103	0.000394	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000102	0.000391	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—WASF2—nicotine dependence	0.0001	0.000383	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—WASF1—nicotine dependence	9.6e-05	0.000368	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—OPRM1—nicotine dependence	9.3e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—DRD2—nicotine dependence	9.13e-05	0.000349	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP2A7—nicotine dependence	8.72e-05	0.000334	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—OPRM1—nicotine dependence	8.65e-05	0.000331	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—DRD2—nicotine dependence	8.31e-05	0.000318	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—DRD2—nicotine dependence	8.24e-05	0.000315	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—DRD2—nicotine dependence	8.13e-05	0.000311	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—DRD2—nicotine dependence	7.7e-05	0.000295	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—DRD2—nicotine dependence	7.57e-05	0.00029	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP2A7—nicotine dependence	6.73e-05	0.000258	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD2—nicotine dependence	6.73e-05	0.000257	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD2—nicotine dependence	6.25e-05	0.000239	CbGpPWpGaD
